{"url_path":"/sec/rkda/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1469443/0001193125-26-223990-index.html","accession_number":"0001193125-26-223990","cik":"0001469443","ticker":"RKDA","issuer_name":"Arcadia Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1469443/0001193125-26-223990-index.html","primary_entity_key":"0001469443","primary_entity_name":"Arcadia Biosciences, Inc."},"word_count":292,"has_tables":true,"body_markdown":"ITEM 6. EXHIBITS\n\nThe following exhibits are attached hereto or are incorporated herein by reference.\n\n \n\n \n\n \n\n \n\n \n\nIncorporated by Reference\n\n \n\n \n\nExhibit\n\nNumber\n\nExhibit Description\n\n \n\nForm\n\n \n\nFile No.\n\n \n\nExhibit\n\n \n\nFiling Date\n\n \n\nFiled Herewith\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.1\n\n \n\n[Form of Preferred Investment Option](https://www.sec.gov/Archives/edgar/data/1469443/000119312526012028/rkda-ex4_1.htm)\n\n \n\n8-K\n\n \n\n001-37383\n\n \n\n4.1\n\n \n\n1/14/2026\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n4.2\n\n \n\n[Form of Placement Agent Preferred Investment Option](https://www.sec.gov/Archives/edgar/data/1469443/000119312526012028/rkda-ex4_4.htm)\n\n \n\n8-K\n\n \n\n \n\n001-37383\n\n \n\n4.4\n\n \n\n1/14/2026\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n10.1\n\n \n\n[Form of Inducement Letter Agreement dated January 9, 2026](https://www.sec.gov/Archives/edgar/data/1469443/000119312526012028/rkda-ex10_1.htm)\n\n \n\n8-K\n\n \n\n \n\n001-37383\n\n \n\n10.1\n\n \n\n1/14/2026\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  31.1\n\n[Principal Executive Officer’s Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](rkda-ex31_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  31.2\n\n[Principal Financial Officer’s Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](rkda-ex31_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  32.1(1)\n\n[Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](rkda-ex32_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  32.2(1)\n\n[Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](rkda-ex32_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.INS\n\nInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.SCH\n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n104.1\n\n \n\nCover page from the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in inline XBRL (and contained in Exhibit 101)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n(1) This certification is deemed not filed for purpose of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.\n\n \n\n \n\n27\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\nArcadia Biosciences, Inc.\n\n \n\n \n\n \n\nMay 14, 2026\n\n \n\nBy:\n\n/s/ THOMAS J. SCHAEFER\n\n \n\n \n\n \n\nThomas J. Schaefer\n\n \n\n \n\n \n\nPresident, Chief Executive Officer and Interim Chief Financial Officer\n\n \n\n \n\n \n\n28"}